Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
6-26-2019 10:30 AM

The Effects of Acute Aerobic Exercise and Caffeine on Working
Memory and Caffeine Withdrawal
Anisa Morava, The University of Western Ontario
Supervisor: Prapavessis, H., The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Arts degree in
Kinesiology
© Anisa Morava 2019

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Cognitive Psychology Commons, and the Psychology of Movement Commons

Recommended Citation
Morava, Anisa, "The Effects of Acute Aerobic Exercise and Caffeine on Working Memory and Caffeine
Withdrawal" (2019). Electronic Thesis and Dissertation Repository. 6249.
https://ir.lib.uwo.ca/etd/6249

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

Abstract
Caffeine is one of the most widely used psychoactive substances worldwide.
Although caffeine elicits cognitive benefits, there are concerns regarding caffeine’s
effects on certain health domains. Acute, aerobic exercise has been shown to improve
cognition. The effects of aerobic exercise in comparison to caffeine on working
memory (WM) in non-caffeine and caffeine consumers remains unknown.
Furthermore, the effects of aerobic exercise in reducing caffeine withdrawal
symptoms has yet to be examined. In Phase I, twenty-nine non-caffeine and thirty
caffeine consumers completed a WM assessment (n-back task), followed by aerobic
exercise and caffeine administration. In Phase II, twenty-five caffeine consumers
underwent a WM assessment and reported caffeine withdrawal symptoms following a
12-hour deprivation period. Aerobic exercise and caffeine administration improved
WM accuracy in both types of consumers and reduced caffeine withdrawal
symptoms. WM performance was not reduced following caffeine deprivation, hence
whether exercise and caffeine could restore WM was not tested.
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Summary for Lay Audience
Caffeine is found in a wide variety of beverages and foods including coffee, tea, softdrinks, energy-drinks, chocolate, and medications. Many individuals consume caffeine daily
to feel alert. Caffeine improves aspects of cognition, which refers to our ability to acquire
and utilize information. Furthermore, caffeine improves feelings of energy and mood.
However, caffeine consumption in certain individuals can have negative health effects such
as increased anxiety and muscle tremors. Caffeine consumption has also been linked to some
negative health effects for pregnant women and their fetuses, such as delayed growth.
Another concern with caffeine consumption is withdrawal symptoms, which occur when a
regular consumer does not consume caffeine. Withdrawal symptoms can include headaches,
tiredness, decreased mood, irritability, and difficulty concentrating. Thus, it is important to
determine if there is an alternative for caffeine that can improve cognition, energy, and
mood, without the negative health effects. The primary aim of this project was to determine
whether twenty minutes of brisk walking would be comparable to ingesting caffeine on a task
that measures your ability briefly hold and update information in your mind. The secondary
aim was to determine whether twenty minutes of brisk walking would be comparable to
ingesting caffeine in reducing withdrawal symptoms after abstaining from caffeine for 12
hours. Our findings suggest brisk walking for 20 minutes can improve cognition and help
reduce caffeine withdrawal symptoms. This research could have an impact on our
understanding of the relationship between aerobic exercise and cognition, as well as how we
can best use aerobic exercise to improve the overall health and well-being of individuals.
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Chapter 1 : Introduction and Literature Review
Caffeine is one of the most widely used psychoactive substances worldwide
(WHO, 2004). A comprehensive assessment of caffeine consumption from the National
Health and Nutrition Examination Survey, found approximately 89% of adults in the
United States (US) consume caffeine regularly (Fulgoni, Keast, & Lieberman, 2015).
Caffeine is present in numerous products such as coffee, tea, soft-drinks, energy-drinks,
chocolate, and medications. The cognitive and mood-enhancing benefits of caffeine have
been cited as one of the primary motivators for its consumption (Temple, Dewey, &
Briatico, 2010; Yeomans, 2010). Caffeine consumption has been specifically associated
with increased energy, alertness, self-confidence, positive mood, and cognitive
performance (Griffiths, Juliano, & Chausmer, 2003). However, for some individuals,
caffeine consumption has been associated with negative effects such as anxiety and
muscle tremors (Alsene et al., 2003; Bovim, Naess, Helle, & Sand, 1995; Childs et al.,
2008). Caffeine has also been identified as a reinforcing and potentially addictive
substance (Ferré, 2016; Hughes et al., 1993). Cessation of caffeine consumption often
results in withdrawal symptoms such as: headache, fatigue, difficulty concentrating, and
decreased contentedness (Juliano & Griffiths, 2004). Taken together, these findings
indicate that although caffeine consumption elicits several benefits to cognition and
mood, there are several concerns regarding caffeine’s potential negative effects and
withdrawal symptoms.
Pharmacokinetics
Caffeine (1,3,7-trimethylxanthine) is an alkaloid derived from the nuts, seeds, and
leaves of numerous plant species (Graham, 1978). Once ingested orally, caffeine is
rapidly absorbed through the small intestine, allowing entry into the bloodstream, and
distribution to bodily tissues (Mumford et al., 1996). Caffeine reaches peak plasma level
in approximately 30 to 60 minutes (Benowitz, 1990). Caffeine is primarily metabolized
by the liver via the cytochrome P450 enzymes (CYP 1A2), with a half-life of
approximately 4 to 6 hours (Benowitz, 1990; Lelo et al., 1986). Cigarette smoking and
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exercise have been documented to significantly reduce caffeine’s half-life, while acute
alcohol consumption, oral contraceptive use, and pregnancy have been shown to
significantly increase caffeine’s half-life (Benowitz, 1990; Collomp et al., 1991; Knutti et
al., 1982; Patwardhan et al., 1980).
Mechanisms of Action
Caffeine’s primary mechanism of action occurs via antagonism of adenosine
receptors in the central nervous system (CNS) (Fredholm et al., 1999). Adenosine is a
neuromodulator primarily responsible for inhibitory effects in the CNS. The presence of
caffeine in the synaptic clefts of CNS neurons results in the blockade of adenosine
binding to adenosine receptors, ultimately promoting “wakefulness” and “alertness”.
Although caffeine acts as an antagonist at all four adenosine sub-receptors (A1, A2A, A2B,
A3), its actions are primarily exerted through interactions at A1 and A2A sub-receptors
(Fredholm et al., 1999). Adenosine receptor antagonism also stimulates release of
neurotransmitters such as dopamine, norepinephrine, and acetylcholine (Carter et al.,
1995; Fredholm & Jonzon, 1988; Hadfield & Milio, 1989). The release of the
aforementioned neurotransmitters has been associated with enhanced motor activity,
arousal, information processing, and attentional control (Acquas et al., 2002; Coull et al.,
1995; Powell, Iuvone, & Holtzman, 2001).
Caffeine Sources and Intake
Caffeine is present in a growing number of foods, beverages, and supplements.
Beyond traditional sources such as coffee, tea, and soft-drinks, caffeine is being added to
candy, gum, and pre-workout supplements (Drewnowski & Rehm, 2016). In a nationally
representative sample of US adults, coffee was found to be the most widely used source
of caffeine (64%), followed by soft-drinks (18%), and tea (16%) (Fulgoni et al., 2015). In
Canada, coffee is the second most consumed beverage by adults and accounts for
approximately 80% of caffeine consumption, followed by tea (12%), and soft-drinks
(6%) (Garriguet, 2008). The amount of caffeine in the above sources varies depending on
the brand and preparation; however, reference values have been compiled by the United
2

States Department of Agriculture (USDA) and the Canadian Nutrient File (CNF; See
Appendix 13). In Canada, the average daily caffeine intake for adults is approximately
2.4mg/kg of body weight (equivalent to approximately 173 mg/day for an individual
weighing the Canadian average of 72.03 kg) (Chou, 1992; Statistics Canada, 2017).
Caffeine Consumption: Risks and Benefits
Caffeine consumption has been associated with risks and benefits to human health
and well-being. Extensive systematic reviews examining caffeine’s effects on human
health suggested caffeine intake below 400 mg/day in healthy adults was not associated
with adverse health effects (Nawrot et al., 2003; Wikoff et al., 2017). However, for a
subset of individuals and for certain populations, caffeine consumption may result in
negative health outcomes. For instance, one of the risks associated with caffeine
consumption is increased anxiety/anxiety-related symptoms. Several studies have
indicated a subset of individuals experience symptoms such as nervousness and
restlessness after consuming caffeine (Alsene et al., 2003; Childs et al., 2008). One
proposed hypothesis suggests possession of genetic variants of the ADORA2A and/or
CYP1A2 genes, which are associated with adenosine receptors and caffeine metabolism,
may be associated with heightened sensitivity to caffeine (Alsene et al., 2003; Childs et
al., 2008; Fulton et al., 2018). In a study investigating the effect of caffeine consumption
in school-aged children, total weekly caffeine intake was a significant predictor of
anxiety after controlling for covariates such as diet, demographics (e.g., sex, school), and
lifestyle (e.g., sleep hours, exercise frequency), indicating caffeine may play a unique
role in inducing anxiety-related symptoms in childhood (Richards & Smith, 2015).
Furthermore, adults with pre-existing anxiety disorders have been documented to
experience exacerbated anxiety symptoms post-caffeine consumption (Bruce et al., 1992;
Nardi et al., 2009).
Another risk associated with caffeine consumption in certain individuals is
increased muscle tremors. Bovim and colleagues (1995) detected reduced motor
steadiness in healthy adults during neuropsychological testing post-caffeine consumption.
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Similarly, in a study examining psychomotor tremors in both low (x̅ =37.07 mg/day) and
moderate (x̅ = 316.2 mg/day) caffeine consumers, greater motor tremors were observed
following caffeine consumption in both groups (Sands et al., 2015). A recent review of
factors affecting tremors in surgeons found caffeine consumption negatively impacted
surgical dexterity. The study authors encouraged reduction of caffeine consumption prior
to conducting a surgical procedure to maintain dexterity (Fargen, Turner, & Spiotta,
2016).
Caffeine use has been associated with both dependence and withdrawal symptoms
upon cessation (Hughes et al., 1991; Strain, Mumford, Silverman, & Griffiths, 1994). A
small proportion of caffeine users (13%) display clinically significant levels of
dependence consisting of “continued use despite psychological or physical harm,
difficulty stopping caffeine use, and using more caffeine than intended” (Juliano &
Griffiths, 2004; Meredith, Juliano, Hughes, & Griffiths, 2013). A larger proportion of
caffeine users report experiencing a wide range of withdrawal symptoms at varying
severities including: headache, fatigue, decreased contentedness, and decreased alertness
(Juliano & Griffiths, 2004; See Section: Caffeine Withdrawal: Subjective and Cognitive
Effects).
When considering subsets of the population vulnerable to the effects of caffeine,
women planning to become pregnant or who are pregnant, have been identified as being
at a greater risk of experiencing adverse health effects due to caffeine consumption.
During pregnancy, the rate of caffeine clearance is significantly reduced, promoting
caffeine accumulation in the body. The accumulated caffeine passes the placental barrier,
potentially resulting in a disrupted neonatal environment (Knutti et al., 1982). Although
numerous studies have investigated the effects of caffeine consumption on both maternal
and fetal health, the results have been mixed. Several studies and reviews have found
caffeine consumption was associated with negative health outcomes such as: delayed
conception, increased risk of spontaneous abortion, preterm birth, low birth weight, and
fetal growth restriction (Bech et al., 2005; Brent et al., 2011; Hahn et al., 2015; Maslova
et al., 2010; Sengpiel et al., 2013). Thus, to mitigate potential harms to fetal development,
4

health agencies such as Health Canada recommend lower caffeine intake limits (i.e.,
<300mg/day) for reproductive-aged women than for the general population (i.e.,
<400mg/day; Nawrot et al., 2003).
Although specific risks are present with caffeine consumption for a proportion of
individuals, caffeine is also associated with benefits to several health domains. Caffeine
consumption has been associated with improved metabolic health outcomes (e.g.,
decreased Type II diabetes risk, increased insulin sensitivity, etc.), decreased risk of
neurological disorders (e.g., Parkinson’s disease), and enhancements to human behaviour
(e.g., cognitive performance, athletic-related performance, and mood; For an in-depth
review see: Nawrot et al., 2003; Pourshahidi et al., 2016). The remainder of this section
will examine caffeine-induced benefits to cognition.
Caffeine and Cognition
Caffeine has been associated with improvements to multiple cognitive domains.
For instance, caffeine is associated with improved information processing, attention, and
specific types of memory (i.e., short-term, episodic, spatial). Caffeine administration has
consistently elicited faster reaction times in both simple and choice reaction time tasks
(Lieberman et al., 1987; Smit & Rogers, 2000). When examining attention, caffeine has
marked effects on measures of sustained attention in both “normal” and “impaired”
conditions, such as following sleep deprivation. Under “normal” conditions, caffeine
administration (200 mg) improved accuracy on both auditory and visual vigilance tasks
(Fagan, Swift, & Tiplady, 1988; Fine et al., 1994). Furthermore, caffeine (200 mg)
improved the number of detected stimuli and reduced reaction times during a 45-minute
visual vigilance task (Olson et al., 2010). Foxe and colleagues (2012) found that
participants who completed the sustained attention to response task (SART) following
caffeine consumption (50 mg) decreased omission errors (not responding to targets) by
50% compared to placebo.
Caffeine exerts similar effects on sustained attention under “impaired” conditions.
In soldiers undergoing sleep deprivation (3 hours of total sleep), caffeine administration
5

resulted in similar performance in a vigilance task compared to non-sleep deprived
controls (McLellan et al., 2005). Kamimori and colleagues (2005) tested participants who
underwent a 29-hour wakeful period on the Psychomotor Vigilance Test (PVT).
Individuals who were provided multiple doses of caffeine during the 29-hour wakeful
period committed less attentional lapses and maintained baseline PVT performance
throughout the entire testing period. Studies examining caffeine’s effects on different
types of memory have found variable results, with some studies detecting benefits and
others finding null effects (Nehlig, 2010). The following section will focus on caffeine
and working memory.
Caffeine and Working Memory
Working memory (WM) has been conceptualized as a system that provides
storage and manipulation of information necessary for cognitive tasks (Baddeley, 1992).
Previous studies show mixed effects of caffeine administration on WM. Addicott and
Laurienti (2009) found administering 250 mg of caffeine to regular caffeine consumers
(2-5 cups of coffee/day) following either 30 hours of caffeine abstinence or normal
caffeine use resulted in improved accuracy (% correct responses) on the n-back task
(continuous performance task assessing WM capacity) in both the abstained and normal
state. Haskell and colleagues (2005) examined the effect of either 75mg or 150mg of
caffeine in both caffeine (x̅ = 217mg/day) and non-caffeine consumers (x̅ = 20mg/day).
Caffeine administration (150mg) significantly improved reaction time on the numeric
WM task in both types of consumers (Haskell et al., 2005). A randomized, double-blind
investigation of the effects of energy drink ingredients on cognitive performance
examined the effects of 200 mg of caffeine on verbal (letter-stimuli), object (shapestimuli), and spatial (shape-stimuli in differing locations) WM tasks. Caffeine reduced
reaction time on the most difficult load of the verbal WM task and increased sensitivity
(an accuracy index composed of hit rate and false alarm rate) across all loads of the
spatial and object WM tasks (Giles et al., 2012).
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Personality type has been found to moderate the effects of caffeine on WM. A
randomized, double-blind, placebo-controlled study examining caffeine, WM, and
personality type (introvert, extrovert) found 200 mg of caffeine improved performance
(% correct responses) on the 3-back load in extraverts (Smillie & Gokçen, 2010).
Furthermore, a study examining the effect of caffeine and personality type on several
components of WM detected similar results at a lower caffeine dose (65mg). Caffeine
interacted with extraversion, improving two components of WM (articulatory loop and
central executive), while also improving simple reaction time and speed of information
encoding across both personality types, suggesting a unique interaction between
extraversion, caffeine, and WM (Smith et al., 2013). A number of studies have not
detected a caffeine-induced improvement to WM (Childs & De Wit, 2006; Koppelstaetter
et al., 2008; Smith, 1999; Warburton, 1995). Warburton (1995) found no change to WM
following caffeine ingestion, but did cite high WM performance in the placebo group,
allowing a small margin for caffeine-driven improvement. Smith (1999) did not find
overall improvement on the WM tasks (serial recall task, running memory task, and
spatial memory task) in the caffeine condition, but did detect improved encoding of new
information in a masked categorical search task, indicating perhaps the tasks chosen to
assess WM were not sensitive enough to detect subtle caffeine-driven changes. Although,
Koppelstaetter and colleagues (2008) did not detect accuracy or reaction time differences
between caffeine and placebo administration on the n-back task, the highest load assessed
in their paradigm was 2-back and previous studies examining the effect of substances
such as nicotine on cognition have indicated the 3-back load is the most sensitive to the
drug effect (Loughead et al., 2009). Koppelstaetter et al (2008) did however determine
via functional magnetic resonance imaging (fMRI) that caffeine modulated neuronal
activity in frontal brain regions associated with executive and attentional functions during
the WM task. In concert, these findings suggest caffeine administration influences WM
processes.
Caffeine Withdrawal: Subjective and Cognitive Effects
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Caffeine has been identified as a reinforcing and addictive substance in murine
models and humans (Griffiths & Woodson, 1988; Hughes et al., 1991). Early research on
human caffeine withdrawal determined caffeine consumers (3-7 coffee cups/day) who
underwent double-blind interleaved periods of caffeinated (100mg) and decaffeinated
coffee consumption displayed withdrawal symptoms, particularly headache, on
decaffeinated days. Furthermore, the presentation of headache predicted selfadministration of caffeinated coffee (Hughes et al., 1991). Several studies have replicated
the presence of withdrawal symptoms following caffeine deprivation with larger sample
sizes (Silverman et al., 1992), as well as characterized the doses at which withdrawal
symptoms occur (Evans & Griffiths, 1999). Caffeine doses as low as 100 mg per day
have been shown to produce withdrawal symptoms upon cessation (Juliano & Griffiths,
2004).
Juliano and Griffiths (2004) conducted an extensive review of human caffeine
withdrawal studies with the objective of characterizing and empirically validating
reported symptoms. Withdrawal symptoms met validity criteria if there was “statistical
demonstration of the symptom in six or more studies that include two or more doubleblind studies that used methodologies in which the conclusion of caffeine withdrawal
effects was not confounded by direct effects of caffeine” (Juliano & Griffiths, 2004). The
following ten caffeine withdrawal symptoms met full validity criteria: headache, fatigue,
decreased energy/activeness, decreased alertness, drowsiness, decreased contentedness,
depressed mood, difficulty concentrating, irritability, and foggy/not clear headed.
Caffeine withdrawal symptoms occur 12 to 24 hours after abstinence and can persist for
several days at varying intensities (Griffiths & Woodson, 1988). Administration of
caffeine post-deprivation has been shown to reduce withdrawal symptom presence and
severity (Addicott & Laurienti, 2009). Although expectancy effects have been raised as a
potential confound in relation to caffeine withdrawal, a recent balanced-placebo study
examining caffeine dose (caffeinated versus decaffeinated) and expectancy (told
caffeinated or told decaffeinated) detected no expectancy effects on withdrawal
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symptoms or cognitive performance, suggesting a pharmacological basis for caffeine
withdrawal (Juliano, Kardel, Harrell, Muench, & Edwards, 2019).
Alongside the subjective effects of caffeine withdrawal, negative effects on
cognitive performance have been detected. Lane and Phillips-Bute (1998) found
overnight caffeine abstinence in regular caffeine consumers (2-10 coffee cups/day)
slowed reaction times and reduced accuracy on a vigilance task. James (1998) replicated
these findings in regular caffeine consumers (3-5 caffeine beverages/day) over a longer
deprivation period (24-hour) on a character recognition task, which assesses information
transfer and short-term memory. Similarly, Yeomans and colleagues (2002) found a 24hour caffeine abstinence period resulted in slower reaction times and increased errors on
the Rapid Visual Information Processing (RVIP) task. However, studies have suggested
the effects of caffeine withdrawal may be reversed. Yeomans et al., (2002) determined
administering 1 mg/kg of caffeine after an overnight abstinence period restored RVIP
task performance (i.e., decreased reaction times and increased response accuracy). An
investigation of caffeine deprivation on cognitive performance, as measured by a choicereaction and n-back task, determined 30 hours of deprivation in regular caffeine
consumers (2-5 coffee cups/day) reduced performance on choice reaction time (Addicott
& Laurienti, 2009). Furthermore, administration of 250 mg of caffeine post deprivation
reduced reaction time on the choice-reaction task and improved accuracy on the 1-back
load of the n-back task (Addicott & Laurienti, 2009). These findings suggest caffeine
deprivation results in withdrawal symptoms and reduces performance on a subset of
cognitive tasks, which are both restored by caffeine administration.
Caffeine Withdrawal Reversal
James (1998) first posited the concept of withdrawal reversal, suggesting caffeine
has limited direct effects, but rather operates by “reversing” withdrawal effects. In 2005,
James and Rogers outlined that several laboratory studies required an overnight
abstinence period before conducting cognitive and subjective assessments, inducing a
caffeine-withdrawn state. Thus, the administration of caffeine in these studies may have
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reduced the negative effects of withdrawal, such as tiredness, rather than represented a
caffeine-driven benefit. To address this concern, several studies have incorporated low to
non-caffeine consumer groups, ad-libitum caffeine consumption, and long-term
withdrawal periods to delineate whether caffeine induces direct effects (Addicott &
Laurienti, 2009; James & Rogers, 2005; Warburton, Bersellini, & Sweeney, 2001).
Heterogeneous results have been reported, with some studies finding direct effects of
caffeine (Addicott & Laurienti, 2009; Childs & deWit, 2006; Haskell et al., 2005 Smith,
Christopher, & Sutherland, 2013), while others finding evidence supporting caffeine
withdrawal reversal (James, 1998; James, Gregg, Kane & Harte, 2005).
Alternative Modalities to Enhance Cognition: Acute Exercise
Given the aforementioned concerns associated with caffeine consumption,
examining alternative modalities to improve cognitive performance is critical. Acute
exercise (single bout) has been suggested as a potential intervention to improve cognitive
performance. Previous studies have shown reliable improvements in cognition following
acute exercise (Chang, Labban, Gapin, & Etnier, 2012; Lambourne & Tomporowski,
2010; Tomporowski, 2003). In a meta-analysis conducted by Chang et al. (2012), the
authors found acute exercise (aerobic, anaerobic, resistance, and combination) had a
small (Hedge’s g = 0.097), but positive effect on cognition. Furthermore, these positive
cognitive effects were found during exercise, immediately following exercise, and after a
delay (Chang et al., 2012). Regarding the assessment of cognitive performance, tasks
gauging executive functions such as the Stroop Task, were more sensitive to the effects
of acute exercise in comparison to other cognitive task types (Chang et al., 2012).
In addition to the above findings, Chang and colleagues (2012) examined
potential moderators of the acute exercise and cognition relationship including: timing of
cognitive assessment, exercise duration, and exercise intensity. When examining timing
of cognitive assessments, testing immediately following exercise resulted in the largest
effect (Cohen’s d = 0.108), followed by testing after a delay (d = 0.103), and testing
during exercise (d = 0.101). When collapsing testing immediately following with delayed
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testing, 11-20 minutes of exercise produced the greatest effect (d = 0.262). Exercise
intensity had differential effects depending on the timing of cognitive testing. Positive
effects on cognition were only observed for very light (d = 0.152), light (d = 0.169), and
moderate intensity exercise (d = 0.120) when cognitive testing occurred immediately
after exercise. When cognitive testing occurred after a delay, positive effects on cognition
were found at every intensity except very light (d = -0.133). Chang et al.’s (2012)
findings suggest acute exercise lasting 11-20 minutes, at an intensity ranging from light
to moderate, may produce the greatest post-exercise cognitive benefit.
Further studies examining the relationship between exercise intensity and
cognitive performance have suggested moderate intensity may confer the greatest postexercise cognitive benefit, particularly in executive functioning (EF) tasks (McMorris,
Sproule, Turner, & Hale, 2011; McMorris & Hale, 2012). McMorris and colleagues
(2011) conducted a meta-analysis of studies utilizing acute, moderate intensity exercise to
enhance EF as assessed by several different tasks (e.g., Flanker Task, Switching Visual
Attention Task, Stroop Task, etc.). Acute, moderate intensity exercise had a strong,
beneficial effect on reaction times in EF tasks (Hedges’ g = -1.41), but a small, negative
effect on accuracy (Hedge’s g = 0.40). In a subsequent investigation of the differential
effects of exercise intensities on cognition speed and accuracy, McMorris and Hale
(2012) detected a small but positive effect size on overall cognitive performance
(Hedge’s g = 0.14). The two studies together suggest the increased arousal elicited by
moderate intensity may result in faster information processing speed. Regarding
accuracy, the small effect may be due to the cognitive assessments lacking the
appropriate sensitivity to detect subtle exercise-induced changes to accuracy (McMorris
& Hale, 2012).
Concerns have been raised regarding whether cardiorespiratory fitness influences
the relationship between acute exercise and cognitive performance. Chang et al. (2014)
addressed these concerns in an investigation of cardiorespiratory fitness, acute exercise,
and executive functioning. Healthy college-aged adults completed a maximal graded
treadmill test to assess cardiorespiratory fitness and were subsequently categorized into
11

low, moderate, and high fitness groups. Individuals in all fitness groups were assessed on
the Stroop Task, which measures executive functioning, pre- and post- completion of 20
minutes of cycling (65% of participant VO2 max). Participants performed better on the
Stroop Task post-exercise, irrespective of cardiorespiratory fitness. However, on the
incongruent condition of the Stroop Task, moderate fitness individuals exhibited the
fastest reaction times, while high fitness individuals exhibited the slowest reaction times,
indicating cardiorespiratory fitness may affect specific domains of information
processing, but not overall performance.
Beyond cognitive functioning, acute exercise has also been shown to provide
other psychological benefits such as improved mood, feelings of energy, and well-being
(Maraki et al., 2005; Loy et al., 2003; Bartholomew, Morrison, & Ciccolo, 2005).
Alongside psychological benefits, acute exercise also confers physical health benefits
such as improved cardiovascular health, skeletal muscle, and immune function
(Rosenwinkel, Bloomfield, & Arwady, 2001 ; Schenk & Horowitz, 2007 ; Rowbottom &
Green, 2000). Thus, acute exercise is a promising alternative for caffeine in that it has
been documented to improve cognitive, psychological, and physical health.
Exercise and Cognition: Mechanisms
Several neurobiological mechanisms have been proposed to underlie the observed
exercise-induced benefits to cognition. The following mechanisms will be reviewed
below: (i) neurogenesis and angiogenesis, (ii) increased neurochemical release, and (iii)
changes to cerebral blood flow and neurotransmitter release. Neurogenesis and
angiogenesis refer to the production of new neurons and blood vessels, respectively. Nonhuman animal studies have indicated aerobic exercise training resulted in neurogenesis,
specifically in the hippocampus, a brain region associated primarily with memory (Creer,
Romberg, Saksida, van Praag & Bussey, 2010; van Praag, Christie, & Gage, 1999). In
addition, following aerobic exercise training, angiogenesis was detected in brain regions
nearby the hippocampus. Some studies have found increased neurogenesis was associated
with improvements in some but not all cognitive tasks (Clark, Brzezinska, Thomas,
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Ryzhenko, Toshkov, & Rhodes, 2008). Taken together, these findings suggest although
there are reliable aerobic exercise-induced structural changes to the brain, the dose of
exercise required and the manner in which the changes promote cognitive function
remain unclear.
Regarding neurochemical changes, two neural growth factors have been identified
as being heavily involved in the exercise-induced benefits to cognitive performance.
Brain-derived neurotrophic factor (BDNF) is a neurotrophin, a protein involved in the
development, function, and survival of neurons (Barde, 1994). BDNF has been identified
as a key component in the neurochemical cascades associated with neuroplasticity
(Huang et al., 2006). Neuroplasticity facilitates learning through modifying neural
connections (Hennigan, O’Callaghan, & Kelly, 2007). Non-human animal studies have
identified that a single bout of exercise increased BDNF levels in the brain (Rasmussen et
al., 2009). Furthermore, a systematic review of acute exercise studies in humans
determined that 69% of studies examining acute, aerobic exercise in healthy individuals
resulted in a “mostly transient increase in serum or plasma BDNF concentration”
(Knaepen, Goekint, Heyman, & Meeusen, 2010). The transient increases in BDNF postexercise may thus promote neuroplasticity in regions contributing to cognition.
The second neurotrophic factor that has been documented to play a role in the
exercise-cognition relationship is insulin-like growth factor 1 (IGF-1; Voss, Nagamatsu,
Liu-Ambrose, & Kramer, 2011). In non-human animals, aerobic exercise has resulted in
elevated IGF-1 production (Trejo, Carro, & Torres-Aleman, 2001). One study found IGF1 and BDNF work in tandem to promote neurogenesis and angiogenesis, particularly in
the hippocampus (Lopez-Lopez, LeRoith, & Torres-Aleman, & 2004; Trejo, Carro, &
Torres-Aleman, 2001). Increases to both neurotrophic factors have been linked to
increased neuroplasticity and other brain network-related changes, however the manner
in which these changes impact cognition warrant further investigation.
The aforementioned mechanisms underlying changes to brain structure typically
operate over time. Thus, mechanisms which operate transiently, such as changes to
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cerebral blood flow (CBF; Vissing, Andersen, & Diemer, 1996) and increased
neurotransmitter release (Dishman, 1997; Wang et al., 2000) are more likely to underlie
the cognitive changes following acute exercise. Several non-human animal studies have
indicated acute exercise-induced changes to CBF (Delp et al., 2001; Vissing, Andersen,
& Diemer, 1996). Human studies have detected changes to the oxygenation of CBF with
concomitant improvements to cognitive performance following acute exercise (Bediz et
al., 2016; Yanagisawa et al., 2010). Regarding neurotransmitter release, non-human
animal studies have consistently shown changes to the release of acetylcholine,
dopamine, epinephrine, and norepinephrine following acute exercise (Kashihara et al.,
2009; Poehlman et al., 1992; Soya et al., 2007). Several human studies have also detected
changes to release of neurotransmitters, namely dopamine and norepinephrine, during
and following acute exercise (McMorris et al., 2008; Wang et al., 2000). Although
several neurotransmitters have been associated with the facilitation of cognitive processes
(Blokland, 1995), the nature of the relationships between acute exercise-induced
neurotransmitter release and cognition remains to be elucidated.
Acute Exercise: Restoring Cognitive Performance and Reducing Withdrawal
Symptoms during Cessation of other Substances
As mentioned previously caffeine deprivation often results in negative effects on
cognitive performance (Addicott & Laurienti, 2009; James, 1998; Phillips-Bute, 1998;
Yeomans et al., 2002 and withdrawal symptoms (Juliano & Griffiths, 2004). With respect
to cognitive performance, there is no literature to support the tenet that cognitive deficits
seen through caffeine deprivation can be restored following an acute bout of exercise.
One indirect non-inferiority study found light-to-moderate intensity exercise
pragmatically increased cognition to a similar level as nicotine in a non-deprived
smoking model (Fagan, Guirguis, Smith, Sui, Rollo, and Prapavessis, unpublished). The
authors concluded that exercise is a healthier alternative to nicotine for cognitive
enhancement and may weaken the maintenance of tobacco use for cognitive
enhancement.
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Cessation of other substances such as nicotine, alcohol, opioids, and
benzodiazepines have also been associated with withdrawal symptoms (WHO, 2018).
Although withdrawal management is often pharmacological in nature, in the context of
smoking cessation (Haasova, Warren, Ussher, Van Rensburg, Faulkner, & Cropley, 2013;
Roberts, Maddison, Simpson, Bullen, & Prapavessis, 2012) and recently alcohol
cessation (Stoutenberg, Rethorst, Lawson, & Read, 2016), acute exercise has been
successfully employed as an intervention to reduce the intensity and frequency of
withdrawal symptoms and cravings. In two comprehensive systematic and meta-analysis
reviews, Roberts et al., (2012) using aggregate data and Haasova et al., (2013) using
individual participant data found weighted mean differences in both “desire to smoke” [1.90 and-2.04 points, respectively] and ‘strength of desire to smoke” [-2.41 and -1.91
points, respectively] that favored the acute exercise condition over the control condition
following a temporary period of abstinence. The effect sizes found in these studies ranged
from d = .4 to 1.9, which are considered moderate-to-large in size (Cohen, 1988).
Furthermore, craving reduction effects lasted up to 30 minutes post-exercise (Ussher,
Cropley, Playle, Mohidin, & West, 2009). Unfortunately, the mechanisms through which
exercise exerts its craving effect are not well understood. Potential mechanisms of action
that have received some support include affect and mood (De Jesus & Prapavessis, 2018),
shifts in attention (Janse Van Rensburg et al., 2012), and cortisol secretion (Roberts et al.,
2015).
Regarding tobacco withdrawal symptoms, light and moderate intensity exercise
significantly reduced symptoms, while vigorous exercise increased symptoms (Roberts et
al., 2012). Withdrawal symptoms positively affected by acute exercise included stress,
difficulty in concentration, tension, restlessness, depression, and irritability (Roberts et
al., 2012). Although the mechanisms underlying exercise-induced reductions to
withdrawal symptoms remain unclear, several biological and cognitive mechanisms have
been proposed. Changes in beta-endorphins, opioids, and cortisol have been identified as
factors potentially mediating the exercise-induced reductions in tobacco withdrawal
symptom reductions (Scerbo et al., 2007). Additionally, heart rate variability (HRV) has
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been identified as a psychophysiological marker that changes following smoking
cessation and exercise, highlighting its potential role in elucidating exercise-driven
withdrawal symptom reduction (Stein et al., 1996; Sandercock, Bromley, & Brodie,
2005). Cognitive changes such as shifts in the allocation of cognitive resources, such as
attention, may also be involved in reducing specific withdrawal symptoms (Ekkekakis &
Acevedo, 2006). Several of the withdrawal symptoms reported in the tobacco cessation
context overlap with caffeine cessation (Irons et al., 2016). The shared symptomatology
lends to assessing the utility of acute exercise in reducing caffeine withdrawal symptoms
during caffeine deprivation.
Summary
There is robust evidence that caffeine leads to improvement in cognitive
performance. Furthermore, when considering the health-concerns associated with
caffeine consumption for specific individuals and subsets of the population, examining
alternative modalities to improve cognitive performance is warranted. An acute bout of
exercise has also shown to enhance cognitive performance, while providing additional
health benefits. To date, the effects of acute exercise in comparison to caffeine on
cognitive performance in both non-caffeine and caffeine users remain unknown.
Furthermore, cognitive deficits and withdrawal symptoms accompany periods of caffeine
deprivation among caffeine users. It also remains unknown whether acute exercise can
reverse these cognitive deficits and withdrawal symptoms to the same extent as caffeine.
Objectives
The objectives of the present study are as follows:
Phase I
i)

To determine the effects of an acute bout of moderate intensity aerobic
exercise and caffeine administration on working memory (WM) in both
non-caffeine and caffeine consumers
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Phase II
i)

To determine whether a 12-hour caffeine deprivation period in caffeine
consumers increases caffeine withdrawal symptoms and reduces WM
performance.

ii)

To determine whether an acute bout of moderate intensity aerobic exercise
and caffeine administration can reduce caffeine withdrawal symptoms and
restore WM performance.

Hypotheses
The hypotheses of the present study are as follows:
Phase I
i)

In comparison to baseline WM performance, aerobic exercise and caffeine
administration will improve WM comparably in both non-caffeine and
caffeine consumers.

Phase II
ii)

A 12-hour caffeine deprivation period in caffeine consumers will increase
caffeine withdrawal symptoms and reduce WM performance.

iii)

Aerobic exercise or caffeine administration will reduce caffeine
withdrawal symptoms and restore WM performance comparably.
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Chapter 2 : Methods
Participants
The inclusion criteria consisted of: (1) aged 18-64 years, (2) ability to read and
write in English, and (3) consumption of less than 30 milligrams of caffeine per day (noncaffeine consumer) or consumption of greater than or equal to 150 milligrams of caffeine
per day (caffeine consumer). The exclusion criteria consisted of: (1) contraindications to
exercise (as assessed by the Physical Activity Readiness Questionnaire), (2) self-reported
cognitive difficulties, (3) self-reported taking of medication for depression or anxiety,
and (4) pregnancy. In (data analyses (See: Table 1). In Phase II, twenty-five participants
(caffeine consumers) completed study procedures.

Age
Sex (% males)
Weight (kg)
Education (%)
Undergraduate
Graduate
Employed
Caffeine Intake (mg)
Weekly
Daily
Time of Last Caffeine Consumption (h)
Years of Caffeine Consumption
Preferred Type of Caffeine Administration
Physical Activity (minutes of MVPA/week)

Caffeine
Consumers
(n = 30)
24.1 (4.8)

Non-Caffeine
Consumers
(n = 29)
24.8 (3.4)

43.3%

51.7%

72.7 (15.1)

70.1(12.2)

50.0%
43.3%
6.67%

13.33%
86.67%
0%

2110.2(1194.8)
301.5 (170.7)

74.7 (64.4)
10.7 (9.8)

10.33 (9.31)
6.7 (4.1)
Coffee
1213 (752.8)

1324.19 (1044.296)

Table 1. Demographics: Means and Standard Deviations (SD)
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Study Design
Phase I
Phase I utilized a randomized counterbalanced crossover design such that each
participant was randomly assigned treatment order (i.e., caffeine administration followed
by exercise or exercise followed by caffeine administration) but completed both
treatments irrespective of being non-caffeine and caffeine consumers. Treatments were
conducted on separate days
Phase II
Phase II involved only caffeine consumers and utilized a randomized design such
that each participant was randomly assigned to receiving either caffeine administration or
exercise following a 12-hour caffeine deprivation period. Randomization was completed
using a computer-generated numbers table.

Figure 1. Study Design (Phase I on the left, Phase II on the right)
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Primary Outcome Measure: Working Memory
Working memory (WM) was assessed through the n-back task. The n-back task
has been widely used in the cognition literature to gauge WM, as it requires both shortterm recognition of and operation on stimuli (Baddeley, 1992; Conway, Kane, Bunting,
Hambrick, Wilhelm, & Engle, 2005). The n-back task consists of a series of stimuli that
are presented rapidly on a screen, with the participant deciding whether the target stimuli
matches the stimuli ‘n’ items back (Jonides, Schumacher, Smith, Lauber, Awh,
Minoshima, & Koeppe, 1997).

Figure 2. n-back task (Jonides et al., 1997)
The n-back task was run on Inquisit (version 4.0.8.0; Millisecond Software,
2008). Instructions for the task are presented on the screen and a practice phase precedes
the evaluation. The participant must score a minimum of 75% of the trials correctly
during the practice phase to proceed to the evaluation. The 75% accuracy threshold was
deemed appropriate for mitigating the learning effect on the n-back task in a previous
study examining WM in smokers and non-smokers (Fagan, Guirguis, Smith, Sui, Rollo,
and Prapavessis, unpublished).
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The n-back task utilized in this study employed letter stimuli. Each letter stimulus
was presented upon the computer screen for 500 milliseconds (ms), followed by a 2000
ms interstimulus (blank screen). The number of stimuli presented changed depending on
the working memory load. For example: 0-back = 48 letters, 1-back = 51 letters, 2-back =
51 letters, and 3-back = 54 letters. The individuals would complete each load (0-back, 1back, 2-back, and 3-back) three times in a randomized order. A correct response would
be when the participant pressed the letter ‘A’ on the keyboard which would indicate the
letter in the sequence is the same as the target letter ‘n’ items back. In the 0-back, the
target letter precedes the assessment for that block, for example, the program states “the
target is W”, hence every time a ‘W’ appears on the screen the individual should press
the ‘A’ key. In the 1-back, a correct response would be if the letter and the consecutive
letter are the same, for example, ‘F’, ‘interstimulus’, ‘F’. In the 2-back, a correct response
would be if a letter matched a previous letter that appeared 2 back in the sequence, for
example ‘T’, ‘interstimulus’, ‘X’ ‘interstimulus’, ‘T’. In the 3-back, a correct response
would be if a letter matched a previous letter that appeared 3 back in the sequence, for
example ‘M’, ‘interstimulus’, ‘P’, ‘interstimulus’, ‘T’ ‘interstimulus’, ‘M’. Reaction time
(ms) and accuracy (percentage of errors) were tabulated for each load. Previous research
has identified the 3-back load as being the most sensitive to drug administration
(Loughead, Wileyto, Valdez, Sanborn, Tang, Strasser, Ruparel, Ray, Gur &, Lerman,
2009). Furthermore, the 3-back load has also been shown to be sensitive to acute exercise
(Tomporowski et al., 2003; Fagan, Guirguis, Smith, Sui, Rollo, and Prapavessis,
unpublished).
Other Measures
Demographics
The following information was collected: age, sex, weight (kg), and education
level.
Caffeine and drug consumption history
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Acute and chronic caffeine history (i.e., approximate time of last caffeine
consumption, amount of years regularly consuming caffeine, preferred type of caffeine
administration) was assessed. Consumption of drugs (i.e., smoking, alcohol) in the past
18 hours was assessed. No participants reported drug consumption 18 hours prior to the
experiment. No participants were smokers.
Physical activity
The Physical Activity Readiness Questionnaire (PAR-Q; Thomas, Reading, &
Shephard, 1992) was utilized to assess ability to participate in physical activity safely.
The PAR-Q is appropriate to administer to individuals aged 15-69 years (Thomas,
Reading, & Shephard, 1992). The PAR-Q has seven items, each with only two possible
response options: yes or no. If a participant indicated yes to any of the seven items they
were deemed not able to participate in physical activity and were thus excluded from the
study (See Appendix 3).
The Short Questionnaire to Assess Health-enhancing Physical Activity
(SQUASH; Wendel-Vos, Schuit, Saris, & Kromhout, 2003) was administered to assess
the frequency, duration, and perceived effort of physical activity during an average week
in four domains: commuting (e.g. walking to school), leisure time (e.g. sports), household
(e.g. washing dishes), and work/school (e.g. walking and standing between working at a
desk) (Wendel-Vos et al., 2003). Frequency and duration are fillable options, such that
the participant is able to indicate the number of days per week, as well as the amount of
hours and minutes they partake in each activity, while perceived effort has three possible
options: slow/light, moderate, and fast/intense. An assessment of the test-retest reliability
of the SQUASH in an adult Dutch population determined acceptable reliability
(Spearman’s correlation = 0.58) (Wendel-Vos et al., 2003). An investigation of the
validity of the SQUASH via doubly labelled water, determined the SQUASH is a valid
self-report tool for assessing physical activity energy expenditure (Campbell, Gaston,
Gray, Rush, Maddison, & Prapavessis, 2016; See Appendix 12).
Caffeine Consumption
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The Caffeine Consumption Questionnaire Revised (CCQ-R; Irons, Bassett,
Prendergast, Landrum, & Heinz, 2016) was administered to assess the consumption of
caffeine-containing products (i.e. beverages, foods, and drugs) during an average week.
The CCQ provides images of caffeine containing products to aid in the estimation of the
serving size of products consumed. The modified CCQ has been shown to have
acceptable reliability (Pearson product moment correlation, r = 0.77). An investigation of
the validity of the CCQ in gauging weekly caffeine consumption determined the CCQ
has acceptable criterion validity (>85% inter-rater agreement) (Irons et al., 2016; See
Appendix 10). CCQ responses were converted to caffeine intake in milligrams/week
using the reference values in Harland (2000; See Appendix 8).
Caffeine Withdrawal
The Caffeine Withdrawal Symptom Questionnaire (CWSQ; Juliano, Huntley,
Harrell, & Westerman, 2012) was utilized to assess the type and severity of caffeine
withdrawal symptoms experienced by the caffeine-consumers. The CWSQ uses twentythree items which focus on seven symptom clusters: (1) fatigue/drowsiness, (2) low
alertness/difficulty concentrating, (3) mood disturbances, (4) low sociability/motivation
to work, (5) nausea/upset stomach, (6) flu-like feelings, and (7) headache. The CWSQ
also includes nine additional items for consideration, four of which have not yet been
empirically validated. Severity of each symptom is assessed on a five-point scale ranging
from 0 (not at all) to 4 (extremely). A higher score reflects greater number of symptoms
and symptom severity. The CWSQ remains in the initial stages of validation and further
studies are warranted to assess its reliability (Juliano et al., 2012; See Appendix 11).
Intervention
Aerobic Exercise
The exercise intervention consisted of a single bout of moderate intensity aerobic
exercise completed on a Woodway PPS treadmill (Woodway, Waukesh, WI). The
intervention consisted of a 2.5 minute warm-up walk, 15 minutes walking at a moderate
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intensity, and a 2.5 minute cool-down walk. Moderate intensity exercise was defined as
40 to 60% of Heart Rate Reserve (HRR; Karvonen, Kentala, & Mustala, 1957; ACSM,
2013). HRR was calculated using the formula (HRmaximum= 220-age) – (HRrest). HRrest was
taken in a seated position prior to exercise with a heart rate monitor. HR during exercise
was also taken with a heart rate monitor. The researcher controlled the speed and incline
of the treadmill to ensure the participant exercised within their moderate intensity HRR
range.
Caffeine Administration
The caffeine administration intervention consisted of oral ingestion of powdered
caffeine. Each participant ingested 1.2mg/kg (body weight) of powdered caffeine
(Sigma–Aldrich Foundation, St Louis, MO) dissolved in 100mL of water (Heatherly,
Hayward, Seers, & Rogers, 2005). The participant then waited in a seated position for 20
minutes to permit caffeine absorption (Mumford, Benowitz, Evans, Kaminski, Preston,
Sanneurd, Silverman, & Griffiths, 1996).
Procedure
The conduct of the study adhered to the Declaration of Helsinki (World Medical
Association, 2013) and the Handbook for Good Clinical Research Practice (WHO, 2005).
Ethical approval was granted from the Western University’s Research Ethics Board
(#110797) (See Appendix 1). All participants read the Letter of Information, had his/her
questions pertaining to the study answered, and signed a Consent Form prior to study
participation.
Participants were recruited from Western University via online advertisements
email, and word-of-mouth. Participants were initially screened for eligibility via email or
an in-person meeting. Screening questions pertained to age (i.e. between 18 and 64),
ability to read and write in English, self-reported caffeine consumption (<30mg/day or
≥150mg/day), contraindications to exercise (i.e. a condition preventing the ability to walk
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on a treadmill for twenty minutes at a moderate intensity), self-reported cognitive
difficulties, self-reported taking of medication for depression or anxiety, and pregnancy.
For those eligible, a first session was scheduled at the Exercise and Health
Psychology Lab (EHPL, www.ehpl.uwo.ca) at Western University. The first session
began with administration of the PAR-Q. If a participant indicated yes to any of the seven
items on the PAR-Q, they were deemed not able to participate in physical activity and
were thus excluded from the study. Upon completion of the PAR-Q, participants were
given the demographic questionnaire, caffeine and drug history questionnaire, SQUASH,
CCQ-R, and CWSQ (caffeine consumers only) to complete.
A non-caffeine consumer was defined as an individual who consumes less than 30
mg of caffeine/day (Kennedy & Haskell, 2011). A caffeine consumer was defined as an
individual who consumes equal to or greater than 150 milligrams of caffeine a day, which
approximately equates to the amount of caffeine in a cup of brewed coffee (Harland,
2000). Non-caffeine consumers completed two one-hour sessions on two separate days
(one exercise session and one caffeine administration session). Caffeine consumers
completed three sessions on three separate days (one exercise session, one caffeine
administration session, and one caffeine deprivation session). The order of sessions (i.e.
caffeine administration followed by exercise or exercise followed by caffeine
administration) was randomized. Participants were scheduled at approximately the same
time to mitigate diurnal effects.
For both non-caffeine and caffeine consumers, blood pressure (BP) was taken in a
seated position with an electronic sphygmomanometer (MPOW). Resting heart rate (HR)
was taken in a seated position with a heart rate monitor (Polar RS100). Weight was
measured using the Health-O-Meter Professional weight scale (Health-O-Meter 500 KL,
Boca Ration, FL) to the nearest 0.1kg. Participants then completed the baseline n-back
task (lasting approximately 10 to 15 minutes) on a portable computer in isolation. Upon
completion of the baseline n-back task, participants completed either the aerobic exercise
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session or the caffeine administration session. HR and BP were again taken at the end of
each treatment session followed by the n-back task.
Participants returned on the second day and followed the same protocol to
complete the treatment session they did not undergo on day one. Caffeine consumers
underwent one additional session, which required a 12-hour caffeine deprivation period
prior to arrival on the third day. Participants were told the researcher would be
biologically confirming caffeine abstinence through a saliva swab, when in fact no
salivary caffeine assays were conducted. This was simply a strategy to increase caffeine
deprivation compliance (Rogers et al., 2003). Participants’ BP and HR were taken in a
seated position upon arrival. They then completed the CWSQ and the n-back task to
assess caffeine-deprived performance. Upon completion of the n-back task, participants
were randomized into receiving either the exercise session or caffeine administration
session. At the end of either session, the CWSQ and n-back were administered again. At
the end of the experimental protocols, participants’ email addresses were entered into a
draw to win a twenty-five-dollar gift card.
Sample Size Analysis
Phase I
Giles and colleagues (2012) detected a change in WM accuracy (composite score
of hit rate and false alarm rate) between placebo and caffeine administration (Cohen’s d =
0.418). Fagan, Guirguis, Smith, Sui, Rollo, and Prapavessis, unpublished detected a change
in WM accuracy (% errors) between baseline and aerobic exercise (Cohen’s d = 0.511).
Based on the above findings, to be adequately powered to detect differences from baseline,
caffeine, and aerobic exercise, a conservative approach of using a small-to-moderate effect
size f = 0.20, power = 0.80, and alpha = 0.05, generated a sample size of 28 individuals
(Cohen 1969; Cohen, 1988; Faul, Erdfelder, Lang, & Buchner, 2007).
Phase II
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In developing the Caffeine Withdrawal Symptom Questionnaire (CWSQ), Juliano
and colleagues (2012) detected a 2.69-point reduction in withdrawal symptoms (Cohen’s
d = 0.866) when caffeine was administered following a 16-hour caffeine deprivation
period. Based on the above findings, to be adequately powered to detect the effects of
caffeine administration following an overnight deprivation period, an approach of using
the effect size of d =0.866, power = 0.80, and alpha = 0.05, generated a sample size of 13
individuals (Cohen 1969; Cohen, 1988; Faul, Erdfelder, Lang, & Buchner, 2007).
Primary and secondary outcome analyses
Phase I
Repeated measures ANOVAs were conducted across baseline, caffeine, and
exercise for both accuracy (% errors) and RT (ms) for non-caffeine and caffeine
consumers on the n-back task. Analyses focused on the 3-back (primary outcome) and 2back (secondary outcome) loads specifically. Means, standard deviations, and 95%
confidence intervals associated with both non-caffeine and caffeine-consumers at all nback loads are presented in Table 2.
Phase II
Repeated measures ANOVAs were conducted across non-deprived, caffeinedeprived, and post-caffeine withdrawal symptom scores as well as non-deprived,
caffeine-deprived and post-exercise withdrawal symptom scores (primary outcome).
Repeated measures ANOVAs were also conducted across non-deprived, caffeinedeprived and post-caffeine accuracy (% errors) and RT (ms) on the n-back task, as well
as non-deprived, caffeine-deprived, and post-exercise accuracy (% errors) and RT (ms)
on the n-back task (secondary outcome). Analyses focused on the 3-back and 2-back
loads specifically.
For both phases, following significant repeated measures ANOVAs, Bonferronicorrected post-hoc t-tests were conducted. The level of significance was accepted at p
<.05 for all tests. Effect sizes (Cohen’s d, η2) accompany all reported findings. All bars
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in figures represent standard deviation (SD). Data were analyzed using IBM SPSS
Statistics (Version 23).
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Chapter 3 : Results
Treatment of Data
Missing data. One non-caffeine participant had no data recorded during the postexercise session and thus was not included in the analyses. Two BP measures from one
participant were not recorded due to equipment malfunction and thus were omitted from
the BP dataset and fidelity check.
Outliers. n-Back trials were excluded if trial RT <150ms (Miller & Low, 2000)
and if the trial was identified as an outlier (>1.5 times the interquartile range above the
upper quartile and below the lower quartile) via boxplots. Less than 3% of total trials
were excluded from the n-Back data set.
Manipulation check (MC). Paired sample t-tests were conducted to determine
whether a time effect (participants performing better on second assessment compared to
first assessment irrespective of treatment) was present. Factorial repeated measures
ANOVAs (2 treatment: caffeine, exercise by 2 treatment order: caffeine first, exercise
first) were also conducted to determine whether treatment by order effects were present.
Non-caffeine consumers MC. All paired sample t-tests were non-significant [3back accuracy, t(28) = 1.231, p = 0.229, d =0.190. 3-back RT, t(28) =-1.218, p = 0.233, d
=0.235. 2-back accuracy, t(28) = 1.231, p = 0.228, d =0.313. 2-back RT, t(28), =-0.800, p
=0.430, d=0.141], indicating no time effects were present. Three-back, factorial repeated
measures ANOVAs found no significant interaction effect for accuracy, F(1,12) =2.292,
p = 0.156, η2 = 0.160 but a significant interaction effect for RT, F(1,12) = 5.866, p
=0.032, η2 = 0.328. For the 2-back, factorial repeated measures ANOVAs found no
significant interaction effects for accuracy, F(1,12) =0.359, p = 0.560, η2 = 0.029 or RT,
F(1,12) =0.519, p =0.485, η2 = 0.041. Taken together, these data show that no treatment
by order effect was present except for RT on the 3-back.
Caffeine consumers MC. All paired sample t-tests were non-significant [3-back
accuracy, t(29) = 1.039, p = 0.307, d =0.213. 3-back RT, t(29) =0.686, p = 0.498, d
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=0.165. 2-back accuracy, t(29) = 0.743, p = 0.464, d =0.187. 2-back RT, t(29), =0.556, p
=0.582, d=0.140], indicating no time effects were present. Three-back, factorial repeated
measures ANOVAs revealed a significant interaction effect for accuracy, F(1,14) =4.807,
p = 0.046, η2 = 0.256. No significant interaction effect was found for RT, F(1,14) =
0.288, p =0.600, η2 = 0.020. For the 2-back, no interaction effect was found for accuracy,
F(1,14) =0.244, p = 0.629, η2 = 0.017 or RT, F(1,14) =0.142, p =0.712, η2 = 0.010. These
data, taken together, suggest there was no treatment by order effect present except for
accuracy on the 3-back.
Fidelity check. A repeated measures ANOVA, followed by post-hoc t-tests were
conducted across pre-exercise, during, and post-exercise treatment for heart rate (HR)
combining both caffeine and non-caffeine consumers. There was a significant effect for
HR [F(2,116) = 754.442, p < 0.000, η2 = 0.929]. Paired sample post-hoc t-tests uncovered
significant increases between pre-exercise and during exercise: t(59)=33.97, p <0.000,
d=5.480, and significant decreases during exercise and post-exercise t(59)=30.260, p
<0.000, d=4.846. A paired sample t-test was conducted between HR prior to caffeine
administration and HR post caffeine administration (20 minutes) combining both caffeine
and non-caffeine consumers. There was a significant decrease in HR [t(58) = 5.117, p <
0.000, d =0.584]. Descriptive HR data can be seen in Table 2 and Table 3.
Paired sample t-tests were conducted between systolic blood pressure (SBP) preexercise and post-exercise, as well as pre-caffeine and post-caffeine. There was no
significant difference in SBP following exercise: [t(57) =0.240, p = 0.811, d =0.048].
There was a significant difference in SBP following caffeine: [t(57) =-2.925, p = 0.005, d
=-0.546 ]. Paired sample t-tests were also conducted between diastolic blood pressure
(DBP) pre-exercise and post-exercise as well as pre-caffeine and post-caffeine
administration. There was no significant difference in DBP following exercise: [t(57)
=0.527, p = 0.600, d = 0.118]. There was no significant difference in DBP following
caffeine: [t(57) =0.125, p = 0.125, d = -0.283]. Descriptive BP data can be seen in Table
4 and Table 5.
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Non-Caffeine Consumers

Caffeine

Both Consumers

Consumers
PreExercise
Exercise

Post
Exercise

71.76 (10.82)

74.36 (11.51)

73.15 (11.01)

121.52 (5.69)

120.18 (5.40)

121 (5.57)

74.51 (13.10)

76.96 (10.72)

75.88 (11.93)

Table 2. Exercise Treatment HR, Values are means and (SD), HR (beats/min)

Non-Caffeine Consumers

Caffeine

Both Consumers

Consumers
PreCaffeine
PostCaffeine

69.03 (9.03)

69.96 (10.2)

69.64 (9.45)

64.45 (9.37)

63.61 (10.5)

64.05 (9.71)

Table 3. Caffeine Treatment HR, Values are means and (SD), HR (beats/min)
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Non-Caffeine

Caffeine Consumers

Both Consumers

Consumers
Pre-

115.11

Exercise

120.43

SBP

(12.24)

PostExercise
SBP
PreExercise
DBP
PostExercise
DBP

(11.63)

119.20

115.68

(11.33)

(14.89)

75.93

71.11

(9.89)

(10.57)

72.93

72.43

(9.75)

(11.92)

117.86 (12.15)

117.5 (13.17)

73.59 (10.42)

72.69 (10.76)

Table 4. Exercise Treatment BP, Values are means and (SD), SBP and DBP (mmHg)

Non-Caffeine

Caffeine Consumers

Both Consumers

Consumers
PreCaffeine
SBP

116.29

117.93

(11.52)

(12.24)
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117.14 (12.36)

PostCaffeine
SBP

PreCaffeine
DBP
PostCaffeine
DBP

119.11

123.33

(12.25)

(13.19)

68.03

74.07

(7.60)

(11.97)

71.96

74.57

(9.63)

(11.85)

121.29 (12.36)

71.16(10.46)

73.31 (10.82)

Table 5. Caffeine Treatment BP, Values are means and (SD), SBP and DBP (mmHg)

Group equivalency (Phase II only). Independent t-tests revealed no significant
treatment group differences (between participants randomized to caffeine and participants
randomized to exercise) for age: t(23)=1.231, p = 0.231, d = 0.490, weight: t(23) = 0.086,
p= 0.932 , d = 0.034, years of caffeine consumption: t(23) =1.105 , p =0.281, d =0.437,
daily caffeine consumption (mg): t(23) = 0.257, p=0.799, d =0.103, non-deprived
caffeine withdrawal scores: t(23): -0.121, p= 0.905, d = 0.048, and MVPA per week
(minutes): t(23)= -0.208, p=0.837, d=0.084. Chi-square tests revealed no significant
group differences for sex χ² (1, n = 25) = 1.066, p = 0.302, Phi = -0.206 and education χ²
(1, n = 25) = 0.051, p = 0.821, Phi =0.045.

Phase I
Primary Outcome (3-back)
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Non-caffeine consumers. A repeated measures ANOVA for 3-back accuracy was
statistically significant: F(2,56)=3.315, p=0.044, η2 =0.106 (see Figure 3). Paired sample
post-hoc t-tests uncovered non-significant differences between baseline and the caffeine
condition: t(28)=2.60, p=0.052, d =0.345, baseline and the exercise condition: t(28)
=2.30, p=0.107, d =0.313, and caffeine and exercise condition t(28) =0.25, p=1.000, d
=0.0148. A repeated measures ANOVA for 3-back RT was not statistically significant:
F(2,56) =1.233, p =0.299, η2 =0.042 (see Figure 4).

% Errors

3-Back Accuracy
22
20
18
16
14
12
10
8
6
4
2
0

*
*

Baseline

Post-Caffeine

Post-Exercise

Figure 3. Changes to accuracy following treatments. Values are means ± SD. *p <0.05

3-Back Reaction Time
1200
1000

RT (ms)

800
600
400
200
0
Baseline

Post-Caffeine

Post-Exercise

Figure 4. Changes to RT following treatments. Values are means ± SD. *p <0.05
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Caffeine consumers. A repeated measures ANOVA for 3-back accuracy was
statistically significant: F(2,58)=6.479, p=0.003, η2 =0.183 (see Figure 5). Paired sample
post-hoc t-tests uncovered significant differences between baseline and the caffeine
condition: t(29) =2.818, p=0.027, d =0.512, and baseline and the exercise condition: t(29)
=3.454, p=0.006, d =0.599. No significant difference was found between the caffeine and
exercise condition t(29) =0.667, p=1.000, d = 0.112. A repeated measures ANOVA for 3back RT was not statistically significant: F(2,58) =1.157, p =0.321, η2 =0.038 (see Figure
6).

3-Back Accuracy
20
18

*

*

16

% Error
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Post-Exercise

Figure 5. Changes to accuracy following treatments. Values are means ± SD. *p <0.05
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Figure 6. Changes to RT following treatments. Values are means ± SD. *p <0.05
Secondary Outcome (2-back)
Non-caffeine consumers. A repeated measures ANOVA for 2-back accuracy was
not statistically significant F(2,56) =2.644, p=0.080, η2 =0.086. A repeated measures
ANOVA for 2-back RT was statistically significant F(2,56) =4.595, p =0.014, η2 =0.141.
Paired sample post-hoc tests uncovered significant differences between baseline and the
caffeine condition only: t(28)=2.786, p=0.028, d =0.527.
Caffeine consumers. A repeated measures ANOVA for 2-back accuracy was
statistically significant F(2,58) =9.179, p=0.000, η2 =0.240. Paired sample post-hoc t-tests
uncovered significant differences between baseline and the caffeine condition only: t(29)
=3.90, p=0.002, d=0.679. A repeated measures ANOVA for 2-back RT was not
statistically significant F(2,58) =2.239, p =0.116, η2 =0.072.
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Means, standard deviations, and 95% confidence intervals for n-Back task

Caffeine Consumers

Trial
M

SD

95% CI

14.33

5.43

761.12

228.71

[675.72, 846.52]

8.26

7.28

[5.54, 10.98]

665.80

174.99

[600.45, 731.14]

5.53

7.69

[2.66, 8.41]

608.62

128.98

[560.45, 656.78]

4.13

7.34

[1.39, 6.88]

496.29

96.54

[460.24, 532.33]

3-back Error %

11.26

6.49

[8.84, 13.69]

3-back RT

714.19

208.50

[636.34, 792.05]

4.37

3.87

[2.93, 5.82]

615.66

166.00

[553.67, 677.65]

2.23

4.28

[0.65, 3.85]

554.52

132.0

[505.23, 603.81]

Baseline
3-back Error %
3-back RT
2-back Error %

2-back RT
1-back Error %
1-back RT
0-back Error %
0-back RT

[12.30, 16.36]

Caffeine

2-back Error %
2-back RT
1-back Error %
1-back RT
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0-back Error %

1.50

4.28

[0.00, 0.31]

487.97

85.96

[455.87, 520.06]

3-back Error %

10.49

7.25

[7.78, 13.20]

3-back RT

737.50

254.86

[640.71, 834.29]

5.88

4.97

[4.02, 7.74]

641.85

219.53

[559.87, 723.82]

5.60

1.81

[-0.12, 1.23]

1-back RT

543.03

140.22

[490.67, 595.39]

0-back Error %

0.694

2.34

[0.18, 1.57]

0-back RT

488.9

78.63

0-back RT
Exercise

2-back Error %
2-back RT
1-back Error %

[459.53, 518.26]

Means, standard deviations, and 95% confidence intervals for n-Back task

Non-Caffeine Consumers

Trial
M

SD

13.06

7.00

789.20

207.90

95% CI

Baseline
3-back Error %
3-back RT
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[10.40, 15.72]
[710.12, 868.28]

2-back Error %

7.23

10.60

[3.20, 11.26]

667.62

189.00

[595.72, 739.52]

2.93

9.096

[-0.53, 6.389]

551.38

162.42

[489.60, 613.16]

0.87

1.55

[0.28, 1.46]

473.88

59.49

[451.25, 496.51]

3-back Error %

10.44

8.13

[7.35, 13.54]

3-back RT

744.93

212.36

[664.15, 825.70]

4.35

9.69

[0.664, 8.03]

577.34

151.62

[519.66, 635.01]

3.54

8.83

[0.183, 6.90]

511.56

94.87

[475.47, 547.65]

1.19

2.88

[0.09, 2.29]

458.82

70.98

[431.82, 485.82]

3-back Error %

10.77

7.59

[7.89, 13.60]

3-back RT

732.44

144.71

[677.40, 787.48]

2-back RT
1-back Error %
1-back RT
0-back Error %
0-back RT
Caffeine

2-back Error %
2-back RT
1-back Error %
1-back RT
0-back Error %
0-back RT
Exercise
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2-back Error %
2-back RT
1-back Error %
1-back RT
0-back Error %
0-back RT

5.47

8.69

[2.17, 8.78]

609.61

145.28

[554.35, 664.87]

2.00

8.20

[-1.00, 6.00]

526.70

127.88

[478.05, 575.33]

2.00

3.60

[0.00, 3.00]

478.34

95.88

[441.87, 514.81]

Table 6. Means, SDs, 95% CI for Non-Caffeine and Caffeine Consumers for all n-back
loads
Phase II
Primary Outcome (Caffeine Withdrawal Symptoms)
A repeated measures ANOVA conducted between non-deprived CWSQ, deprived
CWSQ, and post-caffeine CWSQ scores was statistically significant: F(2,24)=11.058, p =
0.001, η2 = 0.501 (seed Figure 7). Paired sample post-hoc t-tests uncovered significant
differences between baseline and the deprived condition, t(11)= -3.856, p = 0.008,
d=1.35, as well as between the deprived condition and post-caffeine administration:
t(11)= -3.392, p = 0.018, d=1.15.
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*

*

Figure 7. Changes to caffeine withdrawal symptoms from the non-deprived state ,
following 12-hour deprivation, and post caffeine administration. Values are means ± SD.
*p <0.05
A repeated measures ANOVA conducted between non-deprived CWSQ, deprived
CWSQ, and post-exercise CWSQ scores was also statistically significant: F(2,24)=5.786,
p =0.009 η2 = 0.325 (see Figure 8). Paired sample post-hoc t-tests uncovered a significant
difference between baseline and the deprived condition, t(12) = -2.861, p=0.043,
d=1.095, but a non-significant difference between the deprived condition and post
exercise t(12)= -1.338, p = 0.617, d = 0.730.
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*
Figure 8. Changes to caffeine withdrawal symptoms from the non-deprived state , following
12-hour deprivation, and post exercise administration. Values are means ± SD. *p <0.05

Secondary Outcome (3-back)
A repeated measures ANOVA for 3-back accuracy between non-deprived,
deprived, and post-caffeine was not statistically significant: F(2,22) =0.651, p = 0.531, η2
= 0.056 (See Figure 9). A repeated measures ANOVA for 3-back RT between nondeprived, deprived, and post-caffeine was not statistically significant: F(2,22) =0.684, p =
0.515, η2 = 0.059 (See Figure 10). A repeated measures ANOVA for 3-back accuracy
between non-deprived, deprived, and post-exercise was not statistically significant:
F(2,24) = 1.801, p = 0.187, η2 = 0.131 (See Figure 11). A repeated measures ANOVA for
3-back RT between non-deprived, deprived, and post-exercise was not statistically
significant: F(2,24) =0.486, p = 0.621, η2 = 0.039 (See Figure 12).
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Figure 9. Accuracy comparison between non-deprived state, following 12-hour deprivation, and
post-caffeine administration. Values are means ± SD. *p <0.05

RT (ms)

Withdrawal: 3-Back Reaction Time
900
800
700
600
500
400
300
200
100
0
Non-Deprived

Deprived

Post-Caffeine

Figure 10. RT comparison between non-deprived state, following 12-hour deprivation, and postcaffeine administration. Values are means ± SD. *p <0.05
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Figure 11. Accuracy comparison between non-deprived state, following 12-hour deprivation, and
post-exercise administration. Values are means ± SD. *p <0.05
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Figure 12. RT comparison between non-deprived state, following 12-hour deprivation, and postexercise administration. Values are means ± SD. *p <0.05
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Secondary Outcome (2-back)
A repeated measures ANOVA for 2-back accuracy between non-deprived,
deprived, and post-caffeine was not statistically significant: F(2,22) =1.086, p = 0.355, η2
= 0.090. A repeated measures ANOVA for 2-back RT between non-deprived, deprived,
and post-caffeine was not statistically significant: F(2,22) = 1.467, p = 0.252, η2 = 0.118.
A repeated measures ANOVA for 2-back accuracy between non-deprived, deprived, and
post-exercise was not statistically significant: F(2,24) =0.549, p =0.584, η2 = 0.044. A
repeated measures ANOVA for 2-back RT between non-deprived, deprived, and postexercise was not statistically significant: F(2,24) = 1.442, p = 0.256, η2 = 0.107.
Relations between caffeine-deprived WM performance and caffeine withdrawal
symptoms.
Bivariate correlations were conducted between deprived WM performance (3back) and deprived withdrawal symptoms (CWSQ) scores. A Pearson correlation
between deprived 3-back WM accuracy and deprived withdrawal symptoms in the postcaffeine group was not statistically significant: r(10) =0.209, p= 0.514. A Pearson
correlation between deprived 3-back WM accuracy and deprived withdrawal symptoms
in the post-exercise group was not statistically significant: r(11) =0.321, p =0.284.
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Chapter 4 : Discussion
The present investigation sought to determine the effects of acute, aerobic
exercise in comparison to caffeine administration on working memory (WM) in noncaffeine and caffeine consumers. Additionally, the investigation sought to examine the
utility of acute, aerobic exercise in reducing WM deficits and subjective withdrawal
symptoms induced by caffeine deprivation. To begin, I will discuss the Phase I findings,
followed by the Phase II findings.
Phase I
WM performance: Accuracy
In comparison to baseline WM accuracy, caffeine administration and acute,
aerobic exercise improved WM accuracy in non-caffeine (3-back load only) and caffeine
consumers (2- and 3-back loads). In non-caffeine consumers, WM accuracy improved
following both caffeine administration and acute, aerobic exercise. In line with our
hypothesis, caffeine administration and aerobic exercise conferred comparable
improvements to accuracy (absolute percent difference: 2.62%, 2.29% and relative
percent difference: 20.1%, 17.5% respectively). Caffeine administration conferring a
slightly greater accuracy benefit may be due in part to the novelty of caffeine as a
substance for non-caffeine consumers, as prior research has suggested non-caffeine
consumers display heightened physiological and psychological responses to caffeine
(Kennedy & Haskell, 2011). Furthermore, the non-caffeine consumers in this study
reported high physical activity participation (1324 minutes of MVPA/week), suggesting
tolerance of a single-bout of aerobic exercise with little fatigue and discomfort (Chiu &
Barnes, 2003). Previous studies have identified that exercise tolerance is implicated in
exercise-cognition investigations as individuals who do not regularly exercise are more
likely to experience fatigue, which has been associated with impaired cognitive
performance (Brown & Bray, 2015). It is also important to note that our findings
contribute to the body of literature (Haskell et al., 2005; Childs & deWit, 2006; Addicott
& Laurienti, 2009) supporting the notion that caffeine provides net benefits to cognition
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and does not rely completely on the reversal of withdrawal symptoms, as non-caffeine
consumers would not be expected to experience caffeine withdrawal.
In caffeine consumers, aerobic exercise improved accuracy to a greater extent
(absolute percent difference: 3.84%, relative percent difference: 26.8%) than caffeine
administration (absolute percent difference: 3.07%, relative percent difference: 21.4%).
Aerobic exercise conferring a greater benefit to WM accuracy than caffeine may be due
in part to caffeine tolerance (Evans & Griffiths, 1991). The caffeine dose administered
(1.2mg/kg) equates to less than the mean daily caffeine consumption reported by the
caffeine group (301.5mg/day), suggesting these consumers have likely developed some
level of tolerance to the caffeine-driven cognitive effects. Similarly, to the non-caffeine
consumers, caffeine consumers also reported regular participation in physical activity
(1213 minutes of MVPA/week) supporting the notion that a single-bout of aerobic
exercise was tolerated comfortably by this group. It is important to address that a
treatment by order effect was detected for accuracy on the 3-back load in caffeine
consumers, suggesting receiving caffeine on the the first day may have resulted in
improved performance on the second day following acute, aerobic exercise, although
treatment order was counterbalanced. A carry-over effect may have been present and thus
utilizing a wash-out period greater than 24-hours may be required in future
investigations.
Overall, our findings that WM accuracy improvements were detected in both
groups (non-caffeine and caffeine consumers) at only the 2- and 3-back WM loads is in
line with previous work which stated higher WM loads are most sensitive to drug and
behavioural intervention effects (Loughead et al., 2009). Furthermore, our work
substantiates prior findings that acute caffeine administration (Addicott & Laurienti,
2009) and acute exercise improve WM accuracy (Tomporowski et al., 2003).
WM performance: RT
Caffeine administration improved WM RT in comparison to baseline only in noncaffeine consumers on the 2-back load. Aerobic exercise resulted in no improvement to
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WM speed in non-caffeine and caffeine consumers at the 2- and 3-back loads. These
findings differ from those reported by Haskell et al., (2005) and McMorris et al., (2011).
Diverging results could be due to the wide range in administered caffeine doses (Kaplan
et al., 1997), type of cognitive task administered, and exercise intensity (Smit & Rogers,
2000; McMorris et al., 2011). Prior work by our group also detected no changes to RT on
the n-back task following acute, aerobic exercise at a moderate intensity (Fagan et al.,
unpublished). It is important to note when examining the WM speed and accuracy
findings in concert, improved WM was not due to a speed-accuracy trade-off (Reed,
1973). In other words, individuals were not committing less errors on the n-back task at a
cost to response speed. Prior work has suggested caffeine may improve accuracy in
cognitive tasks via increased alertness (Giesbrecht, Rycroft, Rowson, & DeBruin, 2010)
and modulation of neuronal activity in regions associated with attention (Koppelstaetter
et al., 2008). When considering acute, aerobic exercise it has been proposed that exercise
selectively affects the activation and allocation of attentional resources (Sanders , 1983;
Tomporowski et al., 2003).
Phase II
Caffeine Withdrawal Symptoms
A twelve-hour caffeine deprivation period increased subjective caffeine
withdrawal symptoms (14.88-point increase on CWSQ from non-deprived state), which
was in line with our hypothesis and prior work examining caffeine withdrawal (Juliano &
Griffiths, 2004). Moreover, caffeine administration and aerobic exercise reduced caffeine
withdrawal symptoms (12.91-point reduction, 8.07 point-reduction, respectively). Our
results are in line with previous work suggesting caffeine re-administration reduces
caffeine withdrawal symptoms (Addicott & Laurienti, 2009). Furthermore, our study
suggests acute aerobic exercise demonstrates utility in reducing caffeine withdrawal
symptoms, which is a novel finding, as well as provides further evidence that a singlebout of aerobic exercise improves “alertness”, “feelings of energy”, and mood (Maraki et
al., 2005; Loy et al., 2013). In addition, our findings are consistent with work conducted
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in the exercise and tobacco withdrawal literature, which determined acute, aerobic
exercise successfully reduced withdrawal symptoms such as stress, difficulty
concentrating, tension, restlessness, depression, and irritability (Roberts et al., 2012).
When conceptualizing the caffeine deprived phase of this investigation, the notion
of non-inferiority was explored. Non-inferiority trials assess whether a novel intervention
is not unacceptably lesser than a standard of care in clinical research (Rehal et al., 2016).
Non-inferiority trials promote the comparison of advantages that a novel therapy may
have over a standard therapy, such as fewer side effects or lower costs (Bouman et al.,
2015). Caffeine use has been associated with withdrawal symptoms upon cessation in
certain individuals and thus “caffeine-related disorders” have been introduced into the
Diagnostic and Statistical Manual (DSM-5; Hughes et al., 1991; Strain, Mumford,
Silverman, & Griffiths, 1994; Juliano & Griffiths, 2004; Addicott, 2014). Although
caffeine-related disorders have been added to the DSM-5, diagnostic criteria for caffeineuse disorder have not been solidified due to uncertainties regarding caffeine’s abuse
potential and clinically relevant symptomology (APA, 2013). The lack of quantifiable
diagnostic criteria during the time of this investigation barred calculating an appropriate
non-inferiority margin for caffeine withdrawal symptoms to subsequently compare
caffeine administration to acute, aerobic exercise for caffeine withdrawal relief.
WM performance
In contrast to the caffeine withdrawal symptoms, a 12-hour caffeine deprivation
period did not reduce WM performance in caffeine consumers. No significant changes to
WM accuracy or speed were detected between the non-caffeine deprived and caffeinedeprived conditions. These findings were not in line with our hypothesis or with work
conducted by Yeomans et al., 2002. Differing results may be due to the duration of
caffeine-deprivation utilized in our paradigm. Some studies have employed a 24-hour
caffeine deprivation period which may have resulted in greater caffeine withdrawal
severity and in turn greater cognitive deficits (Yeomans et al., 2002; Giles et al., 2012).
Furthermore, when considering the cognitive tasks that were administered in the
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investigations of caffeine withdrawal that detected a caffeine-deprivation induced
cognitive deficit, a variety of cognitive tasks were used (e.g., Rapid Visual Information
Processing task, Attention Network Test) and thus perhaps, the n-back alone may not have
been the most sensitive to detect subtle WM deficits (Heatherely et al., 2004).
Alternatively, the caffeine consumers in our study completed several iterations of the nback task, thus the practice effect may have bolstered WM performance in the caffeinedeprived trials.
Addicott and Laurienti (2009) have also posited participants may exert more effort
during the caffeine-deprived state to compensate for “withdrawal-related fatigue”. Given
that WM performance did not suffer following the 12-hour deprivation period,
improvement to WM via caffeine administration or acute, aerobic exercise was unlikely.
However, it is important to note that WM performance remained stable following both
treatments. Previous literature has suggested that caffeine withdrawal effects worsen with
time and withdrawal related fatigue could result in deteriorating performance on cognitive
tasks (Juliano & Griffiths, 2004; Rogers et al., 2005). Thus, since we detected no change
to WM performance, the caffeine administration and acute, aerobic exercise treatments my
have buffered the caffeine-deprivation effects.
When examining the WM performance and caffeine withdrawal symptoms in
concert, 12-hours of caffeine deprivation did not affect WM performance and caffeine
withdrawal symptoms in the same manner. Twelve-hours of caffeine deprivation resulted
in no significant decrements to WM performance as assessed by the n-back task,
however, caffeine withdrawal symptoms significantly increased. Bivariate correlations
between deprived WM accuracy (3-back load) and deprived CWSQ scores were weakly,
positively correlated, suggesting that caffeine-deprivation may operate on cognition and
caffeine withdrawal symptoms via distinct mechanisms, however, further investigations
are needed to disentangle the effects of caffeine-deprivation.
Strengths, Limitations, Implications, and Future Directions
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The present investigation had numerous strengths. The recruitment of a noncaffeine consumer group allowed our study to address methodological concerns
highlighted in previous studies, as we could further explore whether caffeine-driven
enhancements to cognition represent direct caffeine effects or the reversal of caffeine
withdrawal effects. Furthermore, the use of both cognitive (n-back task) and self-report
(CWSQ) measures following 12-hour caffeine deprivation enabled comparison of
objective and perceived effects of caffeine withdrawal. When considering study design,
the use of a within-subject counterbalanced design in Phase I provided advantages in
terms of reducing variability associated with individual differences, as subjects act as
their own control, as well as minimization of order effects via counterbalancing. Another
strength included administration of the caffeine and aerobic exercise treatments on
separate days, as this minimized carry-over effects and fatigue experienced when
undergoing cognitive testing. The use of a between-subjects randomized design in Phase
II provided advantages in reducing the number of times the n-back was conducted.
Finally, the caffeine dosing utilized in our investigation accounted for participant body
weight, while also being within doses typically consumed in real-world contexts.
Despite the aforementioned strengths, there are limitations to be acknowledged.
One limitation is the practice effect associated with the n-back as well as other cognitive
tasks, which refers to participants improving on the task as a result of repetition of the
task. Future investigations should examine cognitive tasks that are more robust to the
practice effect. Another limitation includes the lack of comparison to a placebo, which in
this investigation was done to reduce the amount of times participants completed the nback task. In the future, a between-groups design could be employed with one group
receiving a placebo condition. Additionally, we detected a treatment by order effect in
caffeine consumers regarding accuracy, which suggests carry-over between treatments
may have been present. Thus, employing a longer wash-out period between treatments
(i.e., > 24 hours) in future investigations may minimize contamination. Finally, the
participants in the present investigation were young, physically active, and highly
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educated. Future research should examine the effects of caffeine and acute aerobic
exercise on WM across various ages, physical activity and education levels.
Determining the duration of the post-caffeine and post-exercise cognitive benefit,
as well as investigating the potential effects of different exercise modalities on cognitive
performance remain areas warranting further investigation. Additionally, examining the
role of biological variables such as caffeine metabolism via genes such as CYP1A2 could
further clarify interactions between metabolism and caffeine-driven changes to cognitive
performance. Finally, exploring the effects of sleep in tandem with caffeine
administration and acute, aerobic exercise on cognitive functioning is another potential
avenue of investigation. Through investigations of this nature, the utility of acute, aerobic
exercise in lieu of caffeine consumption to optimize cognitive performance would be
further clarified with the end-goal of guiding health-related interventions for both general
and special populations.
Conclusion
Findings from the present study suggest caffeine administration and acute, aerobic
exercise improve WM accuracy in both non-caffeine and caffeine consumers.
Furthermore, caffeine administration and acute, aerobic exercise reduce caffeine
withdrawal symptoms induced by a 12-hour caffeine deprivation period. WM is not
reduced during caffeine deprivation, hence whether exercise and caffeine can restore WM
remains unknown. Further research is required to elucidate the mechanisms in which
acute, aerobic exercise exerts its effects on cognition and withdrawal symptoms.
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Appendix 2. Participant Flow Diagram (Non-Caffeine Consumers)
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Appendix 3. Participant Flow Diagram (Caffeine Consumers)
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Appendix 4. Physical Activity Readiness Questionnaire
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Appendix 5. Caffeine Consumption Questionnaire
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CWSQ
Below is a list of feelings/experiences people have. Circle the number that best describes how you are
feeling/what you are experiencing RIGHT NOW.
Not at all

A little

Moderately

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3

4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4

Additional items for consideration:
Queasy
0
Nauseous
0
Vomiting
0
Headachy
0
*Anxious
0
*Nervous
0
*Jittery
0
*Craving for caffeine
0
*Craving for coffee
0

1
1
1
1
1
1
1
1
1

2
2
2
2
2
2
2
2
2

3
3
3
3
3
3
3
3
3

4
4
4
4
4
4
4
4
4

1. Drowsy/sleepy
2. Self-confidence
3. Yawning
4. Alert
5. Tired/Fatigued
6. Content
7. Difficulty Concentrating
8. Irritable
9. Heavy feelings in arms and legs
10. Depressed Mood
11. Grouchy
12. Urge to do work related activity
13. Flu-like feelings
14. Headache
15. Talkative
16. Sluggish
17. Upset stomach
18. Clearheaded
19. Desire to socialize
20. Energetic
21. Nausea/vomiting
22. Muscle pain/stiffness/aches
23. Discouraged

Quite a bit

* These symptoms have not been empirically validated as caffeine withdrawal symptoms
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Appendix 6. Caffeine Withdrawal Symptom Questionnaire

Extremely

Appendix 7. Short Questionnaire to Assess Health Enhancing Physical Activity
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Product

Serving Size
(unless otherwise
stated)

Milligrams of
Caffeine
(approximate values)

oz

ml

Brewed

8

237(1cup)

135

Roasted and ground, percolated

8

237

118

Roasted and ground, filter drip

8

237

179

Roasted and ground, decaffeinated

8

237

3

Instant

8

237

76 - 106

Instant decaffeinated

8

237

5

Coffee

Product

Serving Size
(unless otherwise
stated)

oz

Milligrams of
Caffeine
(approximate values)

ml

Tea

Appendix 8. Caffeine Content (Harland, 2000)
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Average blend

8

237

43

Green

8

237

30

Instant

8

237

15

leaf or bag

8

237

50

Decaffeinated tea

8

237

0

Product

Serving Size
(unless otherwise
stated)

Milligrams of
Caffeine
(approximate values)

oz

ml

Cola beverage, regular

12

355(1 can)

36 - 46

Cola beverage, diet

12

355

39 - 50

Cola Beverages

oz

ml

8

237

Cocoa Products

Chocolate milk

84

8

1 envelope hot-cocoa mix

8

237

5

Candy, milk chocolate

1

28g

7

Candy, sweet chocolate

1

28g

19

Baking chocolate, unsweetened

1

28g

25 - 58

Chocolate cake

2.8

80g

36

Chocolate brownies

1.5

42g

10

Chocolate mousse

3.2

90g

15

Chocolate pudding

5.1

145g

9
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